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included in a logistic regresión, D and Tn remained as the
only independent predictors of outcome. Tn+ lost its pre-
dictive ability in non diabetics (RR = 1.2 against T-; IC
95% = 0.4–3.9; p = 0.77) and increased it in diabetics
(RR = 7.9; IC 95% =1.5–41.0; p = 0.014). In the groups
D-T- and D+T+ the percentage of combinated outcome
were 7.0% and 32.7%, respectively. CONCLUSIONS:
diabetes and Tn are independent predictors of outcome
in the ﬁrst three months after an acute coronary syndrome
without ST segment elevation. Their predictive ability is
additive, so that diabetics with elevated Tn have ﬁve times
the risk of non-diabetics with low Tn. The ability of Tn
to predict major events seems to be lost in non-diabetic
patients.
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OBJECTIVE: The use of cardiac stents is an example of
a technology with both widely discussed cost concerns
and widely adopted use. We examined trends in Medicare
spending overall and for cardiac services from 1995 to
2000 to examine systematic response to the adoption of
this new technology. METHODS: We used all Medicare
hospitalizations from 1995 through 2000. Cases were
identiﬁed for: percutaneous transluminal coronary angio-
plasty (PTCA), stent use, and coronary artery bypass graft
(CABG) surgery. The number of cases, length of stay
(LOS), costs, and total payments were calculated. All
dollar amounts were inﬂated to 2001. RESULTS: Stent
use in PTCA increased from 37% in 1996 to 85% in
2000. The number of PTCAs increased by 91,500 (46%)
from 1995 to 2000 and the number of CABG increased
by 2350 (1.3%). The combined rate for PTCA and CABG
was 12.0 per thousand beneﬁciaries in 2000, an 18.3%
increase since 1995. At $3,000 per case, the cost for stents
was $740 million in 2000. LOS and cost for all PTCAs
decreased from 4.8 days to 3.7 days, and from $14,900
to $13,100. The cost of CABG decreased by $3355 per
case. The cost per beneﬁciary for PTCA and CABG
remained nearly constant and inpatient cardiac care
decreased from $756 per beneﬁciary in 1995 to $698 in
2000. While changes following 1996 cost $1.1 Billion for
stents, other changes in the system saved $6.3 billion.
CONCLUSIONS: While the introduction of stents into
common practice for cardiac care added new costs, com-
pensating changes was induced in the system resulted in
substantial savings. The direct cost of new technologies
is a poor measure of expected system performance. Bal-
anced examination of system costs and clinical perfor-
mance are necessary to avoid irrational fear of short-term
costs at the expense of long-term cost and care 
improvements.
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OBJECTIVE: Cholesterol lowering has been shown 
to reduce cardiovascular morbi-mortality. National and
international (e.g, US NCEP) guidelines have deﬁned
LDL-C treatment initiation levels (TIL) and goals for
patients with different levels of coronary heart disease
(CHD) risk according to the number of CHD risk factors
(CRF) associated to dyslipidemia or to prior CHD. The
objective of this study was to measure the proportions 
of patients above AFSSAPS (French Drug Agency) TIL 
[1CRF > 220mg/dl; 2CRF > 190mg/dl; 3CRFs >
160mg/dl; >3CRFs and prior CHD > 130mg/dl] and
NCEP goal in patients with different CHD risk level and
treated with lipid lowering agents (LLA). METHOD: A
total of 3173 Dyslipidemic patients managed by general
practitioners were randomly selected from a French GPs
computerized database. History of CHD and number of
CRF (age, family history of premature CHD, smoking,
hypertension, HDL-C < 0.9mmol/L, diabetes) were doc-
umented. Percent of patients above AFSSAPS TIL and
NCEP goal was deﬁned for each level of CHD risk.
RESULTS: Twenty-one percent of patients had a history
of CHD. Using AFSSAPS guidelines the distribution of
primary prevention patients according to the number of
CRFs (1, 2, 3, > 3) was 1.6, 25.5, 31.7 and 20.1%, respec-
tively. Almost 40% of CHD patients remained above TIL
and the percentages of primary prevention patients above
TIL varied from 3.9% for patients with 1CRF to 46.5%
for patients with >3CRFs (p < 0.001). Using NCEP guide-
lines, percentage of patients not at goal in the different
CHD risk categories were signiﬁcantly higher and 74.3%
of CHD patients were not at LDL-C treatment goal.
CONCLUSION: Seventy-three percent of patients pre-
scribed LLA were at high CHD risk. Increasing with CHD
risk level, large numbers of patients were above TIL and
LDL-C treatment goal. More effective interventions are
needed in lipid lowering therapy.
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OBJECTIVES: A prospective clinical study was per-
formed to compare the efﬁcacy of low-molecular weight
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heparin and indomethacin in the prevention of deep-vein
thrombosis after total knee arthroplasty in Asian patients.
METHODS: One hundred ﬁfty patients undergoing 
total knee arthroplasty were randomly divided into 
three groups. Group I (the control group) consisted of 51
patients receiving no prophylaxis with an anticoagulant.
Group II consisted of 50 patients receiving the low mol-
ecular weight heparin fraxiparine, and group III consisted
of 49 patients receiving indomethacin. Bilateral ascend-
ing venograms were performed preoperatively and at ﬁve
to seven days postoperatively. A third venogram was 
performed at 3 months in patients who had had a deep
vein thrombosis. RESULTS: The prevalence of deep vein
thrombosis was 71% for the control group versus 50%
for the fraxiparine group (p = 0.042), and 45% for the
indomethacin group (p = 0.011). Deep vein thromboses
were symptomatic in only 28% of the cases, and there
was no pulmonary embolism. CONCLUSIONS:
Fraxiparine and indomethacin signiﬁcantly lowered the
prevalence of deep-vein thrombosis after total knee
arthroplasty as compared with the control. Prophylaxis
for deep vein thrombosis in the Asian population ap-
peared to be warranted. Furthermore, deep-vein throm-
bosis in the calf showed a tendency to improve with 
time.
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OBJECTIVE: We have tried to know the prognostic value
of Troponin T levels (TnT) in patients (p) with a clinical
presentation suggestive of angina, which induced hospi-
tal admission. METHODS: We have followed up 241
consecutive p, 162 male and 79 female, mean age 67.4y.
(range 18 to 89) who initially did not develop a Q-wave
acute myocardial infarction. RESULTS: TnT levels were
higher than 0.1ng/ml in 90p (37%, group TnT+) and
lower than 0.1 in the 63% (group TnT-). Both groups
had comparable age and proportion of women (69 vs. 67
years and 35% vs. 32%, respectively). Every non-Q-wave
infarction p (a = 27) had high levels of TnT. Several
outcome events [death (Dh), heart failure (HF), acute
myocardial infarction (AMI) or need of revascularization
(Rev)] were recalled either by phone or personal interview
three months after the initial clinical episode. Relative
risks and 95% conﬁdence limits of TnT+ for grouped
events considering all the patients was 2.24 for Dh or HF;
2.42 for Dh or AMI; 2.52 for Dh or HF or AMI and 2.14
for Dh, HF, AMI or Rev., and excluding those with non-
Q-wave infarction was 2.66 for Dh or HF; 3.2 for Dh or
AMI; 2.8 for Dh or HF or AMI and 2.66 for Dh, HF,
AMI or Rev. CONCLUSIONS: Patients with chest pain
who require hospitalization due to an admission diagno-
sis of unstable angina or non-Q-wave myocardial infarc-
tion have a different three month outcome depending on
the troponin levels in the ﬁrst 24 hours. Levels higher
than 0.1ng/ml almost triplicate the risk of major events
even when patients with non-Q-wave infarction are
excluded.
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OBJECTIVES: To evaluate the possibility to use data
from insurance companies for assessing the quality of
drug treatment and to assess the prescribing patterns 
for essential hypertension in Slovak Republic (SR).
METHODS: From population of 5 selected counties in
Slovak Republic insured in General Sickness Fund
(509,241 people, almost 10% of population of SR),
81,870 patients were treated for essential hypertension in
2001. Antihypertensive treatment of those patients was
assessed according to the quantity and quality of pre-
scribed drugs. A set of non-speciﬁc and disease-speciﬁc
markers of rationality was developed and used for this
purpose. RESULTS: Average number of daily deﬁned
doses (DDD) for patient was 3537 times a year. The 
most common prescribed antihypertensive group were
angiotensin-converting enzyme inhibitors (126,5DDD on
patient and year). A total of 35% of patients had pre-
scribed less than 150DDDs for a year and almost 10%
had more than 450DDDs from one group of antihy-
pertensives. Great differences between counties were
observed. CONCLUSIONS: Unique characteristic of
Slovak system of issuing prescriptions that require enter-
ing the diagnosis, allows using data from prescriptions for
the quality assessment of drug treatment. The results from
our analysis show low compliance of physicians with
existing guidelines and the need for increased activities
for improving the quality of drug treatment.
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OBJECTIVES: The beneﬁts of repair over replacement
for mitral valve dysfunction are well established.
However, despite growing experience with reparative
surgery, concerns over patients with increased comor-
bidities or requiring concomitant cardiac procedures may
still lead surgeons to elect to perform a more familiar
